GGrantIndex
← Search

Program 3: Cancer BiologyProgram (CBP)

$11,939P30FY2019CANIH

University Of Arizona, Tucson AZ

Investigators

Linked publications, trials & patents

Paper 39631050Paper 39622842Paper 39612086Paper 39361227Paper 39312766Paper 39151774Paper 39100646Paper 39075233Paper 38875929Paper 38858600Paper 38826434Paper 38804255Paper 38769192Paper 38759377Paper 38729260Paper 38719743Paper 38715255Paper 38687603Paper 38658768Paper 38639990Paper 38613866Paper 38612480Paper 38474232Paper 38464045Paper 38453918Paper 38386696Paper 38386396Paper 38328594Paper 38313301Paper 38309054Paper 38291312Paper 38215755Paper 38203706Paper 38199366Paper 38164625Paper 38164604Paper 38097734Paper 38097593Paper 38096366Trial NCT07214506Trial NCT06009926Trial NCT05699603Trial NCT05237960Trial NCT05121051Trial NCT04530552Trial NCT03708055Trial NCT03602066Trial NCT03601507Trial NCT03578432Trial NCT03422536Trial NCT03402230Trial NCT03376971Trial NCT03365895Trial NCT03196180Trial NCT02581137Trial NCT02568566Trial NCT02348203Trial NCT02326805Trial NCT02123849Trial NCT01686165Trial NCT01433913Trial NCT01394211Trial NCT01385280Trial NCT01370889Trial NCT01288261Trial NCT01172028Trial NCT01097304Trial NCT01077453Trial NCT00980395Trial NCT00978718Trial NCT00900432Trial NCT00900341Trial NCT00898703Trial NCT00896935Trial NCT00892268Trial NCT00841204Trial NCT00752739Trial NCT00732498Trial NCT00721877Trial NCT00702299Trial NCT00701857Trial NCT00699907Trial NCT00619060Trial NCT00608634Trial NCT00601640Trial NCT00410618Trial NCT00373022Trial NCT00363805Trial NCT00303823Trial NCT00245024Trial NCT00091325Trial NCT00078897Trial NCT00003307Trial NCT00003082Patent 9486545Patent 9435812Patent 9415110Patent 9262824Patent 5650489Patent 5510240

Abstract

Project Summary / Abstract: Cancer Biology Program (CBP) The goal of the Cancer Biology Program (CBP) is to identify etiologic mechanisms underlying cancer development and progression. As the main basic science of cancer platform for the University of Arizona Cancer Center, the Cancer Biology Program seeks to advance fundamental knowledge of the complex biological networks that are deranged in cancer and to characterize interactions between these complex biological networks and the environment that promote carcinogenesis and tumor progression. Translation of current findings and development of novel approaches to cancer prevention and treatment is facilitated through inter-programmatic collaborations and Cancer Center support. The program is organized into three major themes, including Genomic Instability and Epigenetic Control of Gene Expression, Signaling Networks in Carcinogenesis and Tumor Progression, and Invasion and Metastasis, with four aims: (i) to investigate mechanisms of cancer initiation and progression and to characterize cellular mechanisms that control cancer metastasis, (ii) to identify networks and regulatory pathways as potential markers or targets in prevention and treatment, (iii) to promote intra- and inter-programmatic collaborations to enhance translational research along the continuum from pre-clinical mouse models and human tissue correlates to clinical trials, and (iv) to foster research directions of particular relevance to individuals in Arizona and the Southwest. The Cancer Biology Program achieves these aims through establishment of working groups, conferences and seminars, and development of inter-disciplinary scientific teams; faculty recruitment, membership development and mentoring, and the use of developmental funds to spur targeted research; and, guidance and support of the shared resources. The CBP has 49 Members representing 21 different departments at the University of Arizona. CBP Members have published 390 cancer-relevant manuscripts, of which 30% were intra- programmatic and 36% were inter-programmatic. As of September 1, 2015, the CBP Program secured $11.8M total annual grant dollars with $2.5M from the NCI and $8.3M in other peer-reviewed funding. The CBP has regional impact through its members' basic research into the carcinogenic mechanisms of arsenicals that are pervasive environmental carcinogens in the Southwest. Finally, the Program is invested in using modern, high throughput genomic platforms to develop, enhance, and implement precision medicine. The expanding representation of Hispanic Americans in the State's population impels increased research into cancer health disparities in this population.

View original record on NIH RePORTER →